Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00514904
Other study ID # 109495
Secondary ID 2012-000283-23
Status Completed
Phase Phase 3
First received
Last updated
Start date September 18, 2007
Est. completion date January 6, 2009

Study information

Verified date September 2020
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate, in 2-10 year old subjects, the non-inferiority of meningococcal vaccine GSK134612 compared to licensed meningococcal vaccine Mencevax™. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Description:

Multicentre study with 2 treatment groups. Two blood samples will be taken, prior to and one month after vaccination, from the first 75% enrolled subjects per country independent of the treatment group.


Recruitment information / eligibility

Status Completed
Enrollment 1504
Est. completion date January 6, 2009
Est. primary completion date September 3, 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Years to 10 Years
Eligibility Inclusion Criteria: - Subjects who the investigator believes that their parents or guardians can and will comply with the requirements of the protocol. - A male or female between, and including, 2 and 10 years of age at the time of vaccination. - Written informed consent obtained from the parent or guardian of the subject. - Free of obvious health problems as established by medical history and clinical examination before entering into the study. - Previously completed routine childhood vaccinations to the best of his/her parents'/guardians' knowledge. Exclusion Criteria: - Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. - Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. - Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine. - Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C, W-135 and/or Y (for subjects below 6 years) or within the last five previous years (for subjects 6 years old or above). - Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroups A, C, W-135 and/or Y. - Previous vaccination with tetanus toxoid within the last month. - History of meningococcal disease. - Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination.. - History of reactions or allergic disease likely to be exacerbated by any component of the vaccine(s). - Major congenital defects or serious chronic illness. - Acute disease at the time of enrolment. - Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.

Study Design


Intervention

Biological:
Nimenrix
Single dose, intramuscular injection
Mencevax
Single dose, subcutaneous injection

Locations

Country Name City State
India GSK Investigational Site Goa
India GSK Investigational Site Indore
India GSK Investigational Site New Delhi
India GSK Investigational Site Vellore
Lebanon GSK Investigational Site Beirut
Philippines GSK Investigational Site Sampaloc, Manila
Saudi Arabia GSK Investigational Site Riyadh

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

India,  Lebanon,  Philippines,  Saudi Arabia, 

References & Publications (1)

Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, Bianco V, Van der Wielen M, Gatchalian S, Miller JM. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J. 2011 Apr;30(4):e56-62. doi: 10.1097/INF.0b013e31820e6e02. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects With Vaccine Response to N. Meningitidis Serogroups A (MenA), MenC, MenY and MenW-135 Vaccine response was defined as an rSBA titer of at least 1:32 in subjects initially seronegative (< 1:8) and as 4-fold increase in titer from pre- to post-vaccination in subjects initially seropositive (= 1:8). One month after vaccination (Post-vaccination, study Month 1)
Primary Number of Subjects With Grade 3 General Symptoms (Solicited and Unsolicited) Grade 3 symptom was defined as symptom that prevented normal, everyday activities. During the 4-day (Days 0-3) post-vaccination period
Secondary Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY) Titers Greater Than or Equal (=) to the Cut-off Values The cut-off values for the rSBA titers were = 1:8 and = 1:128 respectively. Pre vaccination (Month 0) and post vaccination (Month 1)
Secondary rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers Antibody titers were expressed as geometric mean titers (GMTs). Pre vaccination (Month 0) and post vaccination (Month 1)
Secondary Number of Subjects With Anti-tetanus Toxoid (Anti-TT) Concentrations Greater Than or Equal to (=) the Cut-off Values The cut-off values for anti-TT concentrations were = 0.1 international units per milliliter (IU/mL) and = 1.0 IU/mL respectively. Pre vaccination (Month 0) and post vaccination (Month 1)
Secondary Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations Antibody concentrations were expressed as geometric mean concentrations (GMCs) Pre vaccination (Month 0) and post vaccination (Month 1)
Secondary Number of Subjects With Anti-polysaccharide (Anti-PS) Concentrations Greater Than or Equal to (=) the Cut-off Values The cut-off values for anti-PS concentrations were = 0.3 microgram per milliliter (µg/mL) and = 2.0 µg/mL respectively for the anti- PSA, anti-PSC, anti-PSW-135 and anti-PSY antibodies respectively. One half of the subjects (50%, randomized) of the ATP cohort for immunogenicity was tested for anti-PSA and anti-PSC and the other half for anti-PSW-135 and anti-PSY. Pre vaccination (Month 0) and post vaccination, (Month 1)
Secondary Anti-polysaccharide (Anti-PS) Antibody Concentrations Anti-PS concentrations were expressed as geometric mean concentrations (GMCs) and expressed in µg/mL. One half of the subjects (50%, randomized) of the ATP cohort for immunogenicity was tested for anti-PSA and anti-PSC and the other half for anti-PSW-135 and anti-PSY. Pre vaccination (Month 0) and post vaccination (Month 1)
Secondary Number of Subjects Less Than (<) 6 Years of Age With Solicited Local Symptoms Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of any local symptom regardless of intensity grade. During the 4-day (Days 0-3) follow-up period after vaccination
Secondary Number of Subjects = 6 Years of Age With Solicited Local Symptoms Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of any local symptom regardless of intensity grade. During the 4-day (Days 0-3) follow-up period after vaccination
Secondary Number of Subjects < 6 Years of Age With Solicited General Symptoms Solicited general symptoms assessed were drowsiness, fever (measured orally and temperature = 37.5°C ), irritability and loss of appetite. Any was defined as incidence of any general symptom regardless of intensity grade or relationship to vaccination. During the 4-day (Days 0-3) follow-up period after vaccination
Secondary Number of Subjects = 6 Years of Age With Solicited General Symptoms Solicited general symptoms assessed were fatigue, fever (measured orally and temperature = 37.5°C ), gastrointestinal and headache. Any was defined as incidence of any general symptom regardless of intensity grade or relationship to vaccination. During the 4-day (Days 0-3) follow-up period after vaccination
Secondary Number of Subjects Reporting Specific Adverse Events (AEs) Specific AEs include: rash; new onset of chronic illness(es) (NOCI) and/ or conditions prompting emergency room (ER) visits or non-routine physician office visits. From Day 0 up to 6 months after vaccination
Secondary Number of Subjects Reporting Any Unsolicited Symptoms Unsolicited symptom covers any symptom reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Up to one month (Day 0-Day 30) after vaccination
Secondary Number of Subjects Reporting Any Serious Adverse Events (SAEs) SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability /incapacity or are a congenital anomaly/ birth defect in the offspring of a study subject. From Day 0 up to 6 months after vaccination
See also
  Status Clinical Trial Phase
Completed NCT03652610 - A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age Phase 2
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Completed NCT00974363 - Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612 Phase 3
Completed NCT00196950 - Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years Phase 2
Completed NCT02173704 - Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. Phase 3
Completed NCT01641042 - Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects Phase 3
Completed NCT01682876 - Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. Phase 3
Completed NCT00758264 - Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration Phase 3
Completed NCT01962207 - The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination Phase 3
Completed NCT00718666 - The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers Phase 2
Completed NCT01939158 - Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine Phase 3
Completed NCT01235975 - Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years Phase 3
Active, not recruiting NCT05082285 - A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants Phase 2
Completed NCT02446743 - Combined Study - Phase 3b MenB Long Term Persistence in Adolescents Phase 3
Completed NCT02946385 - Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents Phase 2
Completed NCT00674583 - Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children Phase 3
Completed NCT01777308 - Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination Phase 3
Completed NCT00464815 - Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects Phase 3
Completed NCT00661557 - Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects Phase 2
Completed NCT00196976 - Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old Phase 2